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Background: Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict
survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop
and externally validate a dynamic prognostic nomogram for overall survival in eSTS survivors for use during
follow-up.
Methods: All primary eSTS patients operated with curative intent between 1994 and 2013 at three
European and one Canadian sarcoma centers formed the development cohort. Patients with Federation
Franc¸aise des Centres de Lutte Contre le Cancer (FNCLCC) grade II and grade III eSTS operated between
2000 and 2016 at seven other European reference centers formed the external validation cohort. We
used a landmark analysis approach and a multivariable Cox model to create a dynamic nomogram; the
prediction window was fixed at five years. A backward procedure based on the Akaike Information Cri-
terion was adopted for variable selection. We tested the nomogram performance in terms of calibra-
tion and discrimination.
Findings: The development and validation cohorts included 3740 and 893 patients, respectively. The var-
iables selected applying the backward procedure were patient’s age, tumor size and its interaction with
landmark time, tumor FNCLCC grade and its interaction with landmark time, histology, and both local
recurrence and distant metastasis (as first event) indicator variables. The nomogram showed good cali-
bration and discrimination. Harrell C indexes at different landmark times were between 0.776
(0.7610.790) and 0.845 (0.8230.862) in the development series and between 0.675 (0.6430.704)
and 0.810 (0.7750.844) in the validation series.
Interpretation: A new dynamic nomogram is available to predict 5-year overall survival at different times dur-
ing the first three years of follow-up in patients operated for primary eSTS. This nomogram allows physiciansKeywords:
Dynamic prediction
Landmark analysis
Prognostic nomogram
Sarcoma
Soft tissue sarcoma: Survivorsncology Society, November 1417, 2018, Rome, Italy.
i.it (A. Gronchi).
pen access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
2 D. Callegaro et al. / EClinicalMedicine 17 (2019) 100215to update the individual survival prediction during follow-up on the basis of baseline variables, time elapsed
from surgery and first-event history.
© 2019 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Research in context
Evidence before this study
We searched PubMed for studies published before Nov 1,
2018, that investigated the use of nomograms for predicting
prognosis of patients with extremity soft tissue sarcoma. We
used the search terms ‘nomogram’, ‘prediction’, ‘sarcoma’, and
‘extremity’. Available prognostic nomograms for patients with
extremity soft tissue sarcoma predicted survival or the occur-
rence of local recurrence or distant metastasis at time of sur-
gery. After surgery, the individual risk of dying shows a
non-linear evolution which is determined by the time elapsed
from surgery, the event history (occurrence of local recurrence
or distant metastasis vs. no events), and by the time-dependent
effect of baseline covariates (tumor and patient characteristics).
At the time of our search, there were no nomograms available
for use during follow-up. The only available dynamic prognostic
model was limited to patients with high-grade tumors, adopted
a suboptimal histological classification and was not externally
validated.
Added value of this study.
With this study, we created and externally validated a
dynamic prognostic nomogram for overall survival to obtain a
longitudinal prognostic estimation for patients with primary
extremity soft tissue sarcoma. In particular, this nomogram
allows individual prognosis prediction at baseline and at differ-
ent time points up to three years after surgery. The main
strengths of this nomogram are the use of easily definable cova-
riates, which were all strongly associated with survival, and the
successful external validation. This nomogram has been incor-
porated in the app ‘Sarculator’ for smartphones and tablets.
Implications of all the available evidence.
With this new nomogram, physicians are now able to
inform patients of their residual risk during follow-up. Psycho-
logically, this may help patients coping with the fear of cancer
recurrence. The longitudinal risk estimation can also aid
personalization of follow-up policies based on the individual-
ized residual risk. Finally, with this instrument physicians are
able to quantify the prognostic impact of local relapse and dis-
tant metastasis in a specific clinical scenario, helping decision-
making in patients who recur.
1. Introduction
Extremity soft tissue sarcomas (eSTS) are characterized by a broad
histological diversity which results in a substantial variation in clini-
cal course [1].
Prognosis estimation for primary eSTS patients has progressed in
recent years with the creation of dedicated prognostic nomograms.
With these tools, physicians are able to compute a personalized prog-
nosis on the basis of baseline clinical variables such as patient’s age,
tumor size, grade and histology [2,3].
Prognostic nomograms for eSTS patients typically predict survival
or the occurrence of an event, namely local recurrence (LR) or distantmetastasis (DM), at time of primary treatment. These static predic-
tions may aid the therapeutic decision making process, for example
identifying patients at higher risk of death or disease recurrence who
may benefit from a combination therapy [2,48]. However, during
follow-up (FU) patient prognosis will change depending on the time
elapsed from primary surgery, the event history (LR vs. DM vs. no
events), and related to the possible time-dependent effect of covari-
ates. As such, “static” nomograms do not provide accurate predictions
if used at a particular time point during FU.
In the past few years there have been studies exploring survival-
specific prognostic information in patients with soft tissue and bone
sarcoma showing that the effect of prognostic variables changes as
patient’s survival time increases and that, without events, the likeli-
hood of surviving improves as time goes by after treatment [913].
Determining the patient’s risk of death or tumor relapse at a cer-
tain time-point given a set of covariates and the event-history until
that moment goes under the broad methodological framework of
“dynamic prediction”. One way to achieve dynamic predictions is to
perform a landmark analysis [14]. This technique involves taking a
‘snapshot’ at a given time, with the creation of a “landmark dataset”
including only the patients at risk at that time point. All the landmark
datasets are stacked in a “super dataset” on which a single regression
analysis (e.g., “Cox supermodel”) can be performed. The first dynamic
nomogram based on landmark analysis was developed for breast can-
cer patients in 2015 proving the feasibility of this approach [15].
The aim of the present study was to develop and externally vali-
date a dynamic prognostic nomogram to predict overall survival (OS)
in primary eSTS survivors at different times during follow-up.2. Methods
2.1. Study design
This is a retrospective analysis. All consecutive adult (>18 years)
patients with primary (non-recurrent, non-metastatic) eSTS surgi-
cally treated at Fondazione IRCCS Istituto Nazionale dei Tumori
(Milan, Italy), Institut Gustave Roussy (Villejuif, France), Mount Sinai
Hospital (Toronto, Canada), and at the Royal Marsden Hospital (Lon-
don, UK) from 1994 to 2013 were merged, forming the development
cohort. On the Milan series, we developed two static nomograms for
OS and DM in 2016 [2]. Patients with the same characteristics oper-
ated on between 2000 and 2016 at 7 other European referral centers
comprised the validation cohort. The full list of participating centers
is available in Supplementary material.
Extremity STS were defined as tumors arising between the shoul-
der girdle and the hand (upper extremity) and between the pelvic
girdle (excluding endopelvic tumours) and the foot (lower extrem-
ity). Patients with well-differentiated liposarcoma, dermatofibrosar-
coma protuberans, desmoid-type fibromatosis, Ewing sarcoma and
alveolar or embryonal rhabdomyosarcoma were excluded.
Tumor margins were classified as microscopically positive (R1) or
negative (R0). Patients who underwent macroscopically incomplete
(R2) resections were excluded. The FNCLCC criteria (grades I, II, and
III) were applied for tumor grading [16].
Histologically, tumors were classified according to the WHO’s cri-
teria and patients were grouped into nine categories [1].
Radiotherapy (RTx) and/or chemotherapy (CTx) were used
according to multidisciplinary guidance or as part of clinical trials.
The follow-up strategy consisted of clinical examination and imaging
D. Callegaro et al. / EClinicalMedicine 17 (2019) 100215 3studies, every 4 months for the first 2 years, every 6 months until the
fifth year and yearly thereafter.
2.2. Ethics
The study was approved by the Institutional Ethics Committee at
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (Study
Protocol: INT 98/15). This research did not require specific written
consent of the patients.
2.3. Statistical analysis
The dynamic nomogramwas developed using a landmark analysis
approach and a multivariable Cox model [14]. A backward procedure
based on the Akaike Information Criterion was adopted for variable
selection [17]. Nomogram performance was tested in terms of cali-
bration and discrimination. The analyses were performed with SASTable 1
Demographic, clinical, and pathological charact
cohorts.
Development Cohort
No. %
Total 3740
Patient’s age, years
Median 56
IQR 4269
Sex
Female 1692 45.2
Male 2048 54.8
N/A 0
Depth
Deep 2615 69.9
Superficial 1125 30.1
N/A 0
Tumor size, cm
Median 6.85
IQR 411
Histological subtype
LMS 478 12.8
DD/pleom lipo 197 5.3
Myxoid lipo 510 13.6
MPNST 201 5.4
Myxofibro 446 11.9
Synovial sarcoma 288 7.7
UPS 796 21.3
Vascular sarcoma 73 2.0
Other 751 20.1
FNCLCC grade
I 665 17.8
II 1233 33.0
III 1842 49.3
Surgical margins
R0 3157 84.4
R1 583 15.6
NA 0
Chemotherapy
done 641 17.1
not done 3099 82.9
N/A 0
Radiotherapy
done 2232 59.7
not done 1508 40.3
N/A 0
Abbreviations: IQR, interquartile range; R0, com
tive margins; R1, complete resection with micro
sarcoma; DD/pleom lipo, dedifferentiated/pleom
liposarcoma; MPNST, malignant peripheral nerv
coma; UPS, undifferentiated pleomorphic sarcom
the Centers for the Fight Against Cancer. * p value
Fisher test, depending on whether the variable
difference between development cohort and vali(Cary, NC, USA) and R software [18]. Statistical methods are detailed
in the Supplementary material.
3. Results
The multicenter series from which we extracted the development
cohort totaled 3752 patients; 12 patients were excluded because sur-
vival time was missing, thus the development cohort included 3740
patients. The validation cohort consisted of 893 patients with grade II
(12.8%) and grade III (87.2%) eSTS. Clinicopathological characteristics
of the two cohorts are listed in Table 1. The median follow-up was
(interquartile [IQ] range) 79 months (44119 months) for the devel-
opment cohort and 71 months (43108 months) for the validation
cohort. In the development and validation cohorts, respectively, 1003
and 367 patients died, including 259 and 55 patients who died with-
out evidence of LR or DM; 263 and 99 patients developed LR; 951
and 482 developed DM as first event; 60 and 180 developederistics of the development and validation
Validation Cohort
No % p value*
893
<0.0001
62
4973
0.8142
357 44.7
441 55.3
95
0.3274
636 71.6
252 28.4
5
<0.0001
8.0
512
<0.0001
43 4.8
37 4.1
2 0.2
78 8.7
189 21.2
107 12.0
357 40.0
16 1.8
64 7.2
<0.0001
0 0
114 12.8
779 87.2
<0.0001
426 61.6
266 38.4
201
<0.0001
46 6.4
671 93.6
176
<0.0001
632 76.3
196 22.7
65
plete resection with microscopically nega-
scopically positive margins; LMS, leiomyo-
orphic liposarcoma; Myxoid lipo, myxoid
e sheath tumor; Myxofibro, myxofibrosar-
a; FNCLCC, French National Federation of
s at Wilcoxon MannWhitney test or exact
is continuous or categorical, for testing the
dation cohort.
Table 2
Final multivariable Cox landmark supermodel for overall survival.
Covariates HR 95% CI P
Age, yearsy <0.0001
69 vs. 42 1.80 (1.58,2.05)
Local recurrence <0.0001
yes vs. no 5.63 (4.26,7.44)
Distant Metastasis <0.0001
yes vs. no 10.34 (8.74,12.23)
Histological subtype <0.0001
LMS vs. Myxoid lipo 1.78 (1.26,2.52)
DD/pleom lipo vs. Myxoid lipo 1.37 (0.93,2.02)
MPNST vs. Myxoid lipo 1.73 (1.16,2.58)
Myxofibro vs. Myxoid lipo 1.05 (0.72,1.53)
Synovial sarcoma vs. Myxoid lipo 2.03 (1.43,2.88)
UPS vs. Myxoid lipo 1.18 (0.85,1.63)
Vascular vs. Myxoid lipo 3.20 (1.85,5.53)
Other vs. Myxoid lipo 1.48 (1.07,2.04)
Size, cm (TLM, mo)y <0.0001
11 vs. 4 (0) 3.06 (2.53,3.70)
11 vs. 4 (12) 2.32 (1.92,2.80)
11 vs. 4 (24) 1.90 (1.55,2.32)
11 vs. 4 (36) 1.65 (1.29,2.11)
FNCLCC grade (TLM, mo) <0.0001
II vs. I (0) 2.55 (1.75, 3.73)
II vs. I (12) 2.07 (1.42, 3.01)
II vs. I (24) 1.63 (1.11, 2.40)
II vs. I (36) 1.26 (0.82, 1.94)
III vs. I (0) 4.88 (3.40,7.02)
III vs. I (12) 2.59 (1.79,3.75)
III vs. I (24) 1.59 (1.08, 2.33)
III vs. I (36) 1.09 (0.72,1.67)
In principle, the HRs could be estimated at the times from 0 to 36 months; we
choose to represent in the Table only four “significant” times: 0, 12, 24 and 36
months. The HR associated to size 11 cm vs. 4 cm tumors was 3.06 at baseline
and dropped down to 1.65 at three years after surgery, and the HR associated
to grade III vs. grade I tumors was 4.88 at baseline and dropped down to 1.09
at three years after surgery. The occurrence of DM and LR were associated
with an increased risk without a time-varying effect (the interaction time by
LR or DM were not retained in the final model according to the backward
selection).
y The two values are, respectively, the 3rd and 1st quartiles of the variable
distribution. Abbreviations: OS, overall survival; HR, hazard ratio; 95% CI, 95%
Confidence Interval; P, p value at Wald test; LMS, leiomyosarcoma; DD/pleom
lipo, dedifferentiated/pleomorphic liposarcoma; Myxoid lipo, myxoid liposar-
coma; MPNST, malignant peripheral nerve sheath tumor; Myxofibro, myxofi-
brosarcoma; UPS, undifferentiated pleomorphic sarcoma; TLM, landmark
time; FNCLCC, French National Federation of the Centers for the Fight Against
Cancer.
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76.0% (74.677.5%) and 10-year OS was 66.3% (64.368.2%). In the
validation cohort 5- and 10-year OS was 59.5% (56.063.1%) and
48.0% (43.852.6%), respectively. Supplementary Fig. 1 shows the OS
curves (panel A; p value at log-rank test<0.00001) and the crude
cumulative incidence curves of LR and DM (panel B; p value at Gray
test: 0.0002 for LR and <0.00001 for DM) in the development and
validation cohorts. Supplementary Figs. 2 and 3 show the number of
patients in the development and validation cohorts at different TLMs
according to LR or DM status. In the development series, OS and CCI
of LR and DM were not significantly different between patients oper-
ated before or after 2005 (Supplementary Fig. 4).
3.1. Dynamic OS nomogram
In the multivariable Cox landmark OS supermodel, after applica-
tion of the backward procedure the following variables were
excluded from the covariates set: tumor’s depth, surgical margin sta-
tus, CTx administration, RTx administration. The final supermodel
included age at surgery, tumor size and its interaction with TLM, grad-
ing and its interaction with TLM, histology, and both LR and DM indi-
cator variables. All selected variables had a significant effect on OS
(all Wald tests p<0.0001; Table 2). For both tumor size and tumor
grade the hazard ratios (HRs) decreased at increasing TLM, indicating
that the strong association with OS characterizing these variables at
baseline became gradually weaker the longer that patients remained
alive during follow-up.
The OS dynamic nomogram derived from the final model (Fig. 1)
allows the computation of the 5-year probability of being alive or,
alternatively by its subtraction from 1, the 5-year probability of dying
from any cause. Prognosis can be estimated at the time of the primary
surgery or at 12, 24 or 36 months after the primary surgery. The pre-
diction window is fixed at 5 years, meaning that, for example, a pre-
diction computed 1 year after surgery provides the probability of
being alive 6 years after surgery. For ease of computation the scores
related to the variable ‘tumor size’ vary according to ‘tumor grade’
and TLM, but this does not imply a statistical interaction between
tumor size and tumor grade, as the model only included interactions
between tumor size by TLM, and grading by TLM. A digital version of
this prediction model has been implemented in the version 2.0 of the
app ‘Sarculator’ (www.sarculator.com). Here, prognosis can be esti-
mated at every three-month interval from the time of the primary
surgery up to three years of follow-up.
Fig. 2 is an example of how the 5-year OS dynamic prediction
varies during follow-up according to an individual patient’s event
history (data shown in Supplementary Table 1 and 2). After surgery,
in the absence of events, the individual risk of dying decreases as
time goes on. This is due to the fact that the population of patients
alive and without events at time x after surgery will have more favor-
able characteristics (absence of LR and DM) as compared to the popu-
lation which, at surgery, share the same set of baseline covariates.
This is because in the landmark model patients who already devel-
oped LR and/or DM or who already died before time x will no longer
be included in the risk set at time x. Fig. 3 and Supplementary Tables
3 and 4 reproduce the two examples of Fig. 2 but using a different
tumor size.
3.2. Nomogram calibration and discriminative ability on development
and validation cohorts
Calibration plots for internal and external calibration are shown in
Fig. 4. Calibration plots for development series patients operated
before or after 2005 are shown in Supplementary Fig. 5.
In the development series, the Harrell C index was (95% bootstrap
confidence interval) 0.776 (0.7610.790) for predictions calculated
at time of primary surgery (TLM=0) and 0.837 (0.8220.851), 0.845(0.8230.862) and 0.834 (0.8110.859) for predictions calculated at
1 year, 2 years and 3 years after surgery, respectively. In the valida-
tion series, the Harrell C index was 0.675 (0.6430.704) at TLM=0,
0.773 (0.7400.801) at TLM=12 months, 0.810 (0.7750.844) at
TLM=24 months and 0.796 (0.7510.834) at TLM=36 months.
4. Discussion
In this study, we developed and externally validated a dynamic
prognostic nomogram to calculate the 5-year survival probability at
different time points over the first three years of FU in patients oper-
ated with curative intent for a primary localized eSTS. With this new
tool, the prognosis estimate can be computed at baseline (primary
surgery) and at any time point up to 3 years after surgery. Also, the
effect of the occurrence of LR or DM has been incorporated. Both in
the development and validation series, this nomogram showed good
discrimination and calibration as proof of its generalizability.
Three clinical needs prompted the development of this new
nomogram.
First, during FU patients often desire an estimate of their residual
survival. In a recent review of advocacy priorities within the sarcoma
community, the issue of survivorship with uncertainties was empha-
sized [19]. Without dynamic models, to update prognosis during FU
Points
0 10 20 30 40 50 60 70 80 90 100
Age years
40
50 60 70 80 90 100
Size cm(T=0 mo,GI)
0 5 10 15 20 25 30 35 40 45Size cm(T=12 mo,GI)
0 5 10 15 25 35 45Size cm(T=24 mo,GI)
0 5 10 25Size cm(T=36 mo,GI)
0 5 10Size cm(T=0 mo,GII)
0 5 10 15 20 25 30 35 40 45Size cm(T=12 mo,GII)
0 5 10 15 25 35 45Size cm(T=24 mo,GII)
0 5 10 25Size cm(T=36 mo,GII)
0 5 10Size cm(T=0 mo,GIII)
0 5 10 15 20 25 30 35 40 45Size cm(T=12 mo,GIII)
0 5 10 15 25 35 45Size cm(T=24 mo,GIII)
0 5 10 25Size cm(T=36 mo,GIII)
0 5 10
Histology
c g i a h
e b d f
Local relapse
No
Yes
Distant metastasis
No
Yes
Total Points
0 20 40 60 80 100 120 140 160
5-year Survival Probability, baseline
0.010.10.20.30.40.50.70.80.90.950.970.98
5-year Survival Probability, post baseline
0.010.10.20.30.40.50.70.80.90.950.970.98
Fig. 1. Overall survival dynamic nomogram. Dynamic nomogram for 5-year overall survival (OS) in patients with primary resected eSTS. The nomogram allows the user to compute
the 5-year survival probability on the basis of patient’s age, tumor size, tumor grade, histology, occurrence of distant metastasis or occurrence of local recurrence as first events. The
prediction can be calculated at baseline (time 0, at surgery) or post baseline (at 1 year, 2 years or 3 years after surgery). The prediction window is fixed at 5 years. Importantly, the
choice of the proper size axis depends upon tumor grade and time at which the prediction is computed. For example, (i) to predict at time 0 (surgery) the 5-year OS of a 60 year-old
patient with a 5 cm G3 MPNST, the user should locate patient’s tumor size on the axis ‘Size cm (T = =0 mo, GIII)’ and draw a line straight upward to the “Points” axis to determine
the score associated with that size and grade (55 points). Then repeat the process for patient’s age at surgery (60 years = 6 points), histologic subtype (10 points), and sum the scores
achieved for each covariate (sum=71 points). Locate this sum on the “Total Points” axis. Draw a line straight down to the “5-year survival probability, baseline” axis to find the pre-
dicted probability (about 78%). (ii) to predict 5-year OS of a patient with the same clinical characteristics as above but who had been operated two years before and has not had any
events during the first two years of follow-up, the user should locate patient’s tumor size on the axis ‘Size cm (T = =24 mo, GIII)’ and draw a line straight upward to the “Points” axis
to determine the score associated with that size and grade (24 points). Then repeat the process for patient’s age at surgery (60 years = 6 points), histologic subtype (10 points), local
relapse (0 points), distant metastasis (0 points) and sum the scores achieved for each covariate (sum=40 points). Locate this sum on the “Total Points” axis. Draw a line straight
down to the “5-year survival probability, post baseline” axis to find the predicted probability (about 94%). Histology abbreviations: (a), leiomyosarcoma; (b), pleomorphic/DD lipo-
sarcoma; (c), myxoid liposarcoma; (d), MPNST; (e), myxofibrosarcoma; (f), other; (g), synovial sarcoma; (h), UPS; (e), vascular sarcoma.
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Fig. 2. Change in 5-year Overall Survival probability over time in different hypothetical clinical scenarios for individual patients. Five-year OS nomogram-predicted probabilities
plotted against the time at which the prediction is computed. Line 1: uneventful follow-up. Line 2: occurrence of LR at 18 months. Line 3: occurrence of DM at 18 months. Panel A:
50-year-old patient operated for a 5 cm, GI, LMS. The predicted 5-year OS probability rises from 95.9% at baseline to 96.9% after two years of FU without events and to 97.4% after
3 years of FU without events. On the contrary, the prognosis of patients who develop LR or DM during FU drops significantly as compared to the baseline prediction, i.e. from 96.0%
at 12 months to 72.1% at 24 months if the patient developed DM. At further uneventful follow-up, the 5-year survival probability will start to rise again. Panel B: 50-year-old patient
operated for a 5 cm, GIII, LMS. The higher grade contributed to a global lowering of 5-year OS predictions. Lines 13 refer to the same event occurrences as in Panel A above. Abbre-
viations: OS, Overall Survival; LMS, leiomyosarcoma, LR: local relapse; DM, distant metastasis.
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Fig. 3. Change in 5-year Overall Survival probability over time in different hypothetical clinical scenario. Five-year OS nomogram-predicted probabilities plotted against the time at
which the prediction is computed. Line 1: uneventful follow-up. Line 2: occurrence of LR at 18 months. Line 3: occurrence of DM at 18 months. Panel A: 50 year-old patient operated
for a 15 cm, GI, LMS. The predicted 5-year OS probability rises from 87.6% at baseline to 94.5% after two years of FU without events and to 96.1% after 3 years of FU without events.
On the contrary, the prognosis of patients who develop LR or DM during FU drops significantly as compared to the baseline prediction, i.e., from 91.2% at 12 months to 55.8% at 24
months if the patient developed DM. At further uneventful follow-up, the 5-year survival probability will start to rise again. Panel B: 50 year-old patient operated for a 15 cm, GIII,
LMS. Line 1: uneventful follow-up. Line 2: occurrence of LR at 18 months. Line 3: occurrence of DM at 18 months. Abbreviations: OS, Overall Survival; LMS, leiomyosarcoma, LR: local
relapse; DM, distant metastasis.
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Fig. 4. Calibration plots of the dynamic Overall Survival nomogram in the development and validation series. Five-year OS at baseline (A) and (E), 12 months (B) and (F), 24 months
(C) and (G) and 36 months (D) and (H). Data are from the development cohort (A)(D) and from the validation cohort (E)(H). The nomogram predicted probabilities were stratified
in equally sized subgroups. For each subgroup, the average nomogram-predicted probability (x-axis) was plotted against the KaplanMeier probability observed in the same sub-
group (y-axis). The 95% CIs of the KaplanMeier estimates are indicated with vertical lines. The continuous line indicates the reference line, where an ideal nomogram would lie.
Abbreviations: TLM, landmark time; OS, overall survival.
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to adapt them in light of the survival curves in the specific scenario,
with potentially inaccurate results. For cancer patients, a very well-
known psychological adverse effect of the natural history of their dis-
ease is the so called Damocle’s syndrome [2022]. This implies that
the cancer patient lives fearing relapse and cancer-related death, in
spite of the fact that it will not occur in an increasingly higher propor-
tion of patients. This certainly contributes to make the notion of cure
in oncology so problematic. It is true that the residual risk of dying of
disease is not nil even after many years, but also that late relapses are
rare, though with marked differences from cancer to cancer [23].
Actually, patient prognosis improve with time, at a non-steady speed.
Psychologically, therefore, it may be very important for the cancer
patient to be updated about the evolution with time of his/her risk
profile. He/she might be surprised realizing which is the residual risk.
Updating the patient on a contact-by-contact basis may strengthen
the information process about risks and may overcome misunder-
standings related to dichotomous information (by which, say, before
5 years the risk would be high, and beyond it would be nil). This
nomogram may improve patient information during follow-up in the
STS field, and serve as a model in oncology.
The second need is personalizing follow-up policies. The need of
improving and personalizing FU strategies was identified as a priority
by advocacy groups [19]. This nomogram will allow patients to
improve their risk perception during follow-up. This awareness, will
lay the foundation for a shared decision making and physicians will
be able to actively engage patients into choosing a follow-up strategy
that could best suit their individual preferences and values on the
basis of a personalized dynamic risk estimation. A shared decision
making is particularly important in a scenario like this where there is
no right or wrong path (i.e. intensive vs. non-intensive follow-up)
and a diagnostic test can trigger patient anxiety as well as a number
of other investigations [24]. Of course, there is an issue of efficacy
about follow-up. By and large, we lack formal demonstrations of effi-
cacy of follow-up as such. Indeed, several randomized trials in some
common cancers were negative [25,26]. It is difficult to foresee prag-
matic trials on the efficacy of follow-up in STS. Clearly, follow-up pol-
icies might be modeled. It is somewhat arbitrary to model such
policies in the lack of data about the added value of an earlier diagno-
sis. However, if the predicted prognosis were very different at differ-
ent intervals, at least there could be a rationale in narrowing follow-
up windows, and vice versa. Thus, an instrument such as this nomo-
gram might help personalize follow-up policies in STS patients, even
in the lack of strong data about efficacy.
The third need is to personalize the approach to patients who develop
LR/DM. Treatment decisions at relapse are often challenging. Our nomo-
gram allows quantifying the negative prognostic implication of an onco-
logical event in a single patient and this may aid in the decision-making
process in the recurrent/metastatic setting as well as it may improve
patient stratification in clinical trials in themetastatic setting.
In our new nomogram, the prediction window is fixed at 5 years
while the time-point at which the prediction can be computed can
vary from baseline to up to three years after surgery. Over the first
three years of follow-up the risk of death among eSTS patients is sub-
stantially higher than after that time point when the risk drops signif-
icantly. This is related to the tendency of the DM curves to plateau
after three years in the most common histological subtypes among
eSTS [27,28]. Our nomogram covers the period of time during which
updating the survival prediction is needed the most.
With the backward statistical approach, tumor depth, surgical
margin status, CTx and RTx administration were excluded from the
nomogram covariate set, as well as their interactions with TLM. This is
consistent with the findings in our two previous static nomograms
for OS and DM and it is not surprising since tumor depth and margin
status have been shown to have limited influence on survival in other
studies while RTx administration was not associated with animproved survival in randomized controlled trials [2,2931]. With
regard to CTx, it is unlikely to be able to identify a possible effect on
OS in such a diverse population which included both high risk and
low risk patients. A propensity score-matched analysis recently per-
formed on the development cohort showed a non-significant 5% sur-
vival benefit associated with CTx administration [32].
In our nomogram, the prediction is derived from the following cova-
riates: patient age at surgery, tumor size, tumor grade, histology, occur-
rence of LR and occurrence of DM. Patient’s age and histology are static
covariates whose value and HRs do not vary with time (their interac-
tions with TLM was not retained in the model). In this nomogram we
adopted the 4th Edition (2013) of the WHO histological classification to
categorize patients into 9 groups. Both the granularity of the histological
classification and the modeling of patient age as continuous variable are
added values of this nomogram [33]. Analysis of the impact of both
tumor size and grade showed that the more time that elapsed from sur-
gery, the weaker became their association with survival (Table 2). This
is consistent with other studies, in particular with what was observed
by Parsons et al. in a population-based conditional survival analysis of
more than 6000 primary eSTS patients treated with surgery in which
the HR related to tumor size and grade decreased with increased time
from diagnosis [10,34]. Finally, LR and DM are dynamic covariates,
whose value (yes vs. no) may vary with time; however, their time-
dependent effect was weak and their interaction with TLM was not
selected in the final model. The occurrence of DM is the stronger risk
factor for OS with an HR of 10.34 while the HR related to the occurrence
of LR is 5.63. This is likely due to the fact that in eSTS an isolated LR is
unlikely to directly cause a patient’s death, if we exclude the very proxi-
mal locations that may recur within the pelvis/chest. Interestingly, as
noted in Figs. 2 and 3, in patients with higher risk tumors the negative
prognostic impact of LR and/or DM is more pronounced.
One strength of this study is the robustness of the prediction
model. By merging more than 3700 eSTS patients in a unique devel-
opment cohort, we were able to capture the time-dependent effect of
tumor size and grade. The long median FU of the development cohort
allowed us to stretch the predictions out to 5 years, which means
that a prediction computed 3 years after surgery allows estimating
the probability of being alive 8 years after surgery. Of note, there was
a good agreement between observed and nomogram predicted OS
when splitting the development series in the two subsets of patients
operated in the Nineties and more recently (calibration plots in Sup-
plementary Fig. 5). This makes us confident in extending nomogram
use to future patients treated according to the more recent policies.
At external validation, although calibration for a limited subgroup of
patients was not as accurate as with the internal cohort, this model
still showed good discrimination with Harrell C indexes of 0.675,
0.773, 0.810 and 0.796 at the four analysed timepoints (baseline, 12,
24, 36 months). These results compare favorably with the internal
validation of a dynamic prognostic nomogram predicting 5-year OS
after the start of adjuvant endocrine therapy in postmenopausal,
endocrine-sensitive early breast cancer patients [15]. This is true
especially bearing in mind that our nomogram was validated on an
independent external cohort and that the development and valida-
tion cohorts were intrinsically different in terms of baseline charac-
teristics and outcomes (Table 1, Supplementary Fig. 1). Nonetheless,
we cannot infer that this nomogram is universally applicable. The
external validation has been successful on a series of patients oper-
ated among reference centers that share the same treatment guide-
lines and in countries with similar life expectancy. The validity of this
nomogram on more diverse populations, in low-volume centers or
among centers that use different treatment guidelines should be
tested to further strengthen the adoption of this instrument into clin-
ical practice.
Compared to previous studies [13], our nomogram adds signifi-
cant insights since it is built on a larger cohort, is valid for patients
with grade I eSTS as well as higher grade tumors, adopts a more
8 D. Callegaro et al. / EClinicalMedicine 17 (2019) 100215updated and granular histological classification and included an
external validation. Moreover, we were able to select easily definable
covariates which were all strongly associated with survival.
This study has limitations. First, the low number of patients
experiencing concurrent LR and DM (n = =60) did not allow us to sepa-
rate the OS probability estimation for this subgroup of patients and
they were considered as metastatic. Second, since the nomogram model
was based on the first occurrence of LR or DM, it is not able to factor in
the effect of a second LR or DM on survival. In particular, the post-event
survival curves reflect the outcome of both patients who will experi-
ence second events as well as those who do not. In general, this nomo-
gram should not be used if a patient experiences other events after the
first LR and/or the first DM. Finally, since the external validation was
performed in a population of only grade II and III eSTS, we cannot infer
whether this model is generalizable to patients with grade I tumors
operated outside the centers included in the development cohort.
In conclusion, this new prognostic tool fulfills a need of the
oncologist dealing with eSTS patients: being able to objectively coun-
sel patients regarding their personalized residual risk during FU.
Patients might be comforted from an improvement in prognosis as
the time goes by without events and the update of the prognostic
estimate may also support patients’ planning for the future. More-
over, the dynamic prediction informs the physician of how a postop-
erative event will impact on an individual patient’s prognosis
quantitatively. Finally, this study paves the way for future FU person-
alization with possible creation of risk-adapted FU strategies. This
new nomogram has also been incorporated in the app ‘Sarculator’ for
smartphones and tablets, which is available for free download [35].
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